<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01065246</url>
  </required_header>
  <id_info>
    <org_study_id>IP-CAT-AC-04</org_study_id>
    <secondary_id>2009-014076-22</secondary_id>
    <nct_id>NCT01065246</nct_id>
  </id_info>
  <brief_title>Safety Study of Second Intraperitoneal (I.P.) Infusion Cycle of Catumaxomab in Patients With Malignant Ascites</brief_title>
  <acronym>SECIMAS</acronym>
  <official_title>Phase II Open Label Study to Evaluate the Safety of a Second I.P. Infusion Cycle of Catumaxomab in Patients With Malignant Ascites Due to Carcinoma, Requiring Their First Therapeutic Puncture After Treatment in the CASIMAS Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neovii Biotech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neovii Biotech</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II single arm, open-label study investigate the safety of a second cycle of
      catumaxomab in patients with malignant ascites due to carcinoma, requiring their first
      therapeutic puncture after treatment in the CASIMAS study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 30 evaluable patients from the CASIMAS study will be enrolled. Catumaxomab will be
      infused intraperitoneally with 3hour constant-rate infusions 4 times within 11 days with
      ascending dosages (10 - 20 - 50 - 150 µg).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>proportion of patients who are able to receive a second cycle of catumaxomab</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>puncture free survival</measure>
    <time_frame>1-3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence and severity of adverse events</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of human-anti-mouse antibodies</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Malignant Ascites Due to Epithelial Carcinoma</condition>
  <arm_group>
    <arm_group_label>catumaxomab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>catumaxomab</intervention_name>
    <description>4 intraperitoneal infusions within 11 days administered over 3 hours via an indwelling catheter at the following doses: 10 - 20 - 50 - 150 µg catumaxomab</description>
    <arm_group_label>catumaxomab</arm_group_label>
    <other_name>Removab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients who have completed 4 infusions of catumaxomab in the CASIMAS study

          -  age &gt;= 18 years

          -  Karnofsky index &gt;= 60 %

          -  patients with malignant ascites requiring their first therapeutic ascites paracentesis
             after at least 60days following last catumaxomab infusion in the CASIMAS study

          -  Patients where standard therapy is either not available or no longer feasible

        Exclusion Criteria:

          -  acute or chronic infection

          -  concomitant treatment with investigational products other than catumaxomab, cancer,
             chemo- or radiotherapy

          -  previous treatment with entirely murine monoclonal antibodies other than catumaxomab

          -  liver metastases with volume &gt;70 % of liver metastasized tissue
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jalid Sehouli, MD, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité Campus Virchow Clinic Berlin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charité Campus Virchow Clinic</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Heiss MM, Ströhlein MA, Jäger M, Kimmig R, Burges A, Schoberth A, Jauch KW, Schildberg FW, Lindhofer H. Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer. 2005 Nov 10;117(3):435-43.</citation>
    <PMID>15906359</PMID>
  </reference>
  <reference>
    <citation>Ruf P, Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood. 2001 Oct 15;98(8):2526-34.</citation>
    <PMID>11588051</PMID>
  </reference>
  <reference>
    <citation>Riesenberg R, Buchner A, Pohla H, Lindhofer H. Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3). J Histochem Cytochem. 2001 Jul;49(7):911-7.</citation>
    <PMID>11410615</PMID>
  </reference>
  <reference>
    <citation>Zeidler R, Mysliwietz J, Csánady M, Walz A, Ziegler I, Schmitt B, Wollenberg B, Lindhofer H. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer. 2000 Jul;83(2):261-6.</citation>
    <PMID>10901380</PMID>
  </reference>
  <reference>
    <citation>Zeidler R, Reisbach G, Wollenberg B, Lang S, Chaubal S, Schmitt B, Lindhofer H. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol. 1999 Aug 1;163(3):1246-52.</citation>
    <PMID>10415020</PMID>
  </reference>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2010</study_first_submitted>
  <study_first_submitted_qc>February 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2010</study_first_posted>
  <last_update_submitted>October 2, 2012</last_update_submitted>
  <last_update_submitted_qc>October 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>malignant ascites</keyword>
  <keyword>second cycle</keyword>
  <keyword>trifunctional</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Bispecific</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

